deferasirox has been researched along with Agnogenic Myeloid Metaplasia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Abruzzese, E; Auteri, G; Bartoletti, D; Benevolo, G; Bergamaschi, M; Biale, L; Bonifacio, M; Breccia, M; Bucelli, C; Caocci, G; Caramella, M; Carmosino, I; Cattaneo, D; Cilloni, D; Crisà , E; Di Veroli, A; Elli, EM; Gambacorti-Passerini, C; Iurlo, A; Latagliata, R; Markovic, U; Palandri, F; Palumbo, GA; Polverelli, N; Porrini, R; Pugliese, N; Renso, R; Scaffidi, L; Tiribelli, M; Trawinska, MM | 1 |
| Bazargan, A; Chai, KL; Kostos, L; Tam, CS | 1 |
| Antolini, L; Aroldi, A; Caramella, M; Carraro, MC; Carrer, A; Casartelli, E; D'Adda, M; Elli, EM; Gambacorti-Passerini, C; Gardellini, A; Iurlo, A; Maffioli, M; Malato, S; Orofino, N; Passamonti, F; Polverelli, N; Rossi, M | 1 |
| Ihling, C; Tesch, H | 1 |
| Giagounidis, A; Groepper, S; Haferlach, C; Schlue, J | 1 |
| Arruga, F; Cilloni, D; Messa, E; Messa, F; Roetto, A; Saglio, G | 1 |
| Capalbo, S; Franzese, MG; Palumbo, G; Spinosa, G | 1 |
| Kato, J; Matsuki, E; Matsumoto, K; Nakaya, A; Okamoto, S; Yamane, A | 1 |
8 other study(ies) available for deferasirox and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Topics: Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Retrospective Studies | 2022 |
The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
Topics: Aged; Benzoates; Bone Marrow; Deferasirox; Erythropoiesis; Female; Humans; Image-Guided Biopsy; Immunohistochemistry; Iron Chelating Agents; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Positron-Emission Tomography; Primary Myelofibrosis; Triazoles | 2017 |
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Topics: Aged; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Primary Myelofibrosis; Retrospective Studies | 2019 |
Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Primary Myelofibrosis; Spherocytosis, Hereditary; Treatment Outcome; Triazoles | 2013 |
Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.
Topics: Benzoates; Blood Transfusion; Combined Modality Therapy; Deferasirox; Humans; Iron Chelating Agents; Primary Myelofibrosis; Remission Induction; Treatment Outcome; Triazoles | 2016 |
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2008 |
Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.
Topics: Aged; Benzoates; Blood Transfusion; Deferasirox; Female; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2009 |
[Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes].
Topics: Aged; Aged, 80 and over; Benzoates; Deferasirox; Erythrocyte Transfusion; Female; Hematopoiesis; Humans; Iron Chelating Agents; Iron Overload; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis; Treatment Outcome; Triazoles | 2012 |